Skip to main content

Table 2 Correlation between TOP2A expression and response to Pegylated Lyposomal Doxorubicin (PLD) in terms of time to progression (TTP)

From: TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers

Time To Progression (TTP) to PLD TOP2A < 18% TOP2A ≥ 18% p-value
All patients, months (CI 95%) 4,5 (3,1-5,9) 6,7 (4,8-8,6) 0,085
TTP according to Platinum Free Interval
 PR 3,7 (2,6-4,9) 4,9 (2,9-6,9) 0,445
 PPS 5,6 (2,7-8,6) 9,1 (5,8-12,4) 0,185
TTP according to chemoterapeutic regimen
 PLD monotherapy 3,4 (2,5-4,3) 5,8 (3,7-3,9) 0,035
 Carboplatin-PLD 8,0 (3,5-12,4) 9,6 (5,7-13,5) 0,796
 PLD-Trabectidin 1,8 (0,6-3,2) 3,5 (0,6-6,3) 0,358
  1. TTP time to progression, CI confidence interval, PR Platinum-resistant patients, PPS partially platinum-sensitive patients